Lung Cancer, Nonsmall Cell Clinical Trial
Official title:
Effect Of Exercise Training In Patients With Lung Cancer During Chemotherapy Treatment
Verified date | April 2022 |
Source | Riphah International University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the effects of exercise training in patients with lung cancer during chemotherapy treatment. In currently accessible literature, majority studies, met-analysis, and systemic reviews are related to surgical procedures and post-op pulmonary Rehabilitation of patients with Lung cancer. In literature, Gap related to the control group was observed also. The current study aimed to fulfill this gap by planning a structured intervention plan for the control group as well. It will also add in literature the deficiency of oncology rehab for patients receiving chemotherapy only.
Status | Completed |
Enrollment | 40 |
Est. completion date | April 1, 2022 |
Est. primary completion date | April 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 55 Years |
Eligibility | Inclusion Criteria: - Diagnosed patients of stage 1 and 2 Non-small cell lung carcinoma (NSCLC) including Adenocarcinoma & squamous cell carcinoma The diagnosis was established within 6 wk prior to enrollment and was confirmed by histology. Participants are undergoing lung cancer chemotherapy Participant has the willingness to participate in training WHO physical fitness scores 0-1 Able to perform 6-minute walk test (6MWT) at baseline Exclusion Criteria: - • Participant with history of trauma and surgery - Patients with lung disease other than lung cancer - Uncontrolled hypertension or unstable coronary artery disease. - Severe OA, bone or CNS metastases. - hemoglobin <10 g/dL - Lower than 3,500 white blood cells per microliter of blood |
Country | Name | City | State |
---|---|---|---|
Pakistan | Institute of Radiotherapy and Nuclear Medicine | Peshawar | KPK |
Lead Sponsor | Collaborator |
---|---|
Riphah International University |
Pakistan,
Davis KM, Kelly SP, Luta G, Tomko C, Miller AB, Taylor KL. The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors. Urology. 2014 Aug;84(2):300-6. doi: 10.1016/j.urology.2014.04.036. Epub 2014 Jun 26. — View Citation
Vainshelboim B, Fox BD, Saute M, Sagie A, Yehoshua L, Fuks L, Schneer S, Kramer MR. Limitations in exercise and functional capacity in long-term postpneumonectomy patients. J Cardiopulm Rehabil Prev. 2015 Jan-Feb;35(1):56-64. doi: 10.1097/HCR.0000000000000085. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6 min walk test: Distance (meters) | Changes from the baseline, 6 min walk test (6 MWT) was used to measure Functional capacity. It is a sub maximal exercise test which can aid in assessing functional capacity of patients with cardiopulmonary diseases, in this test we find out the maximum distance in meters which an individual covers in 6 min without any support. | 4 weeks | |
Primary | Forced Expiratory Volume in 1 second (FEV1) | Changes from the Baseline, the digital spirometer is used in clinical setting to analyze Forced Expiratory Volume in 1 second FEV1 in Liters | 4 weeks | |
Primary | Forced vital Capacity (FVC) | Changes From the Baseline, the digital spirometer is used in clinical setting to analyze Forced vital Capacity in Liters | 4 weeks | |
Primary | Rate of perceived exertion (RPE) | Changes From the Baseline, measured through Borg RPE scale which measures a person's perception of their effort and exertion breathlessness, and fatigue during physical work rating between 1 and 10. The higher the number, the more intense the exercise. An RPE of 1 is often referred to as just above rest, hardly any exertion, while an RPE of 10 is a maximal effort. | 4 weeks | |
Secondary | Mindfulness | Changes From the Baseline, measured through MAAS. The MAAS is a 15-item scale designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present. The scale shows strong psychometric properties and has been validated with college, community, and cancer patient samples.Higher scores reflect higher levels of dispositional mindfulness | 4 weeks | |
Secondary | Hospital Anxiety and Depression | The Hospital Anxiety and Depression Scale (HADS) is a frequently used self-rating scale developed to assess psychological distress in non-psychiatric patients. HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score >8 denotes anxiety or depression | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06003075 -
Induction Chemo-Nivo in Unresectable Stage III NSCLC
|
Phase 2 | |
Enrolling by invitation |
NCT06293833 -
Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan
|
N/A | |
Recruiting |
NCT03705806 -
Palliative Thoracic ImmunoRT
|
||
Not yet recruiting |
NCT06060964 -
Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management
|
Early Phase 1 | |
Completed |
NCT04634630 -
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
|
||
Completed |
NCT03689634 -
Move For Surgery - A Novel Preconditioning Program
|
Phase 3 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Completed |
NCT03902834 -
Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic Surgery
|
N/A | |
Active, not recruiting |
NCT03322072 -
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
|
N/A | |
Completed |
NCT02995889 -
FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer
|
N/A | |
Recruiting |
NCT04237805 -
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT05061940 -
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
|
||
Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
Suspended |
NCT02991651 -
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
|
Phase 1 | |
Enrolling by invitation |
NCT04678440 -
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
|
Early Phase 1 | |
Recruiting |
NCT04222335 -
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
|
N/A | |
Recruiting |
NCT04415320 -
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
|
Phase 2 | |
Recruiting |
NCT02786589 -
Plasmodium Immunotherapy for Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05085028 -
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
Completed |
NCT05956782 -
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
|
N/A |